Reducing Cognitive Impairment in Glioma with Repetitive Transcranial Magnetic Stimulation and Cognitive Strategy Training
- Conditions
- GliomaCognitive Impairment
- Interventions
- Device: repetitive transcranial magnetic stimulation (rTMS)Behavioral: cognitive strategy training
- Registration Number
- NCT06043765
- Lead Sponsor
- Linda Douw
- Brief Summary
The TRUE-GRIT study will assess the feasibility of a study protocol investigating the efficacy of a combination therapy consisting of cognitive strategy training (CST) and repetitive transcranial magnetic stimulation (rTMS) to reduce cognitive impairment in adult glioma patients. This study is part of the GRIP-project, a project aimed at investigating interventions for improving quality of life in brain tumor patients.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 16
- ≥ 18 years of age
- Histological diagnosis of diffuse glioma (WHO grade 2,3, or 4)
- Subjective cognitive impairment, defined as CFQ-score ≥ 44
- Being able to give informed consent and undergo treatment and measurements based on researchers insight
- Stable disease, i.e. no oncological treatment for ≤ 2 months prior to inclusion; no radiological progression on the most recent MRI, not older than 6 months, and no clinical progression at inclusion
- Stable dosage (for at least 8 weeks) of anti-epileptic medication
- Current pregnancy or have given birth less than three months ago
- Current other treatment for cognitive complaints
- Karnofsky performance score <70
- A tumor located in the parietal cortex
- TMS exclusion: implanted medical devices (e.g. pacemaker, deep brain stimulator, cochlear implants, medical infusion device, etc.); metal in the body; sleep deprivation
- MRI exclusion: extreme claustrophobia or metallic objects in or on the body
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Cognitive strategy training + real rTMS repetitive transcranial magnetic stimulation (rTMS) Verum rTMS to PPC contralateral to the tumor (3000 10Hz pulses at 110% RMT, 30 10-s trains, 30s inter-trial interval, 20 mins total) Cognitive strategy training + real rTMS cognitive strategy training Verum rTMS to PPC contralateral to the tumor (3000 10Hz pulses at 110% RMT, 30 10-s trains, 30s inter-trial interval, 20 mins total) Cognitive strategy training + sham rTMS repetitive transcranial magnetic stimulation (rTMS) Sham rTMS to PPC contralateral to the tumor (3000 10Hz pulses at 110% RMT, 30 10-s trains, 30s inter-trial interval, 20 mins total). Cognitive strategy training + sham rTMS cognitive strategy training Sham rTMS to PPC contralateral to the tumor (3000 10Hz pulses at 110% RMT, 30 10-s trains, 30s inter-trial interval, 20 mins total).
- Primary Outcome Measures
Name Time Method Number of patients completing intervention and study protocol Baseline versus directly post-intervention (max. 11 weeks after baseline) The feasibility will be assessed by number of patients completing the intervention and obligatory study measurements
- Secondary Outcome Measures
Name Time Method Tolerability and side effects of the combination therapy Weekly during the intervention (7 weeks) Tolerability and side-effects will be assessed with an in-house-made questionnaire (with yes/no and open questions)
Trial Locations
- Locations (1)
VU University Medical Centers, location VUmc
🇳🇱Amsterdam, Netherlands